Biotronik, Inc. v. Medtronic USA, Inc.

840 F. Supp. 2d 1251, 2012 WL 14031, 2012 U.S. Dist. LEXIS 890
CourtDistrict Court, D. Oregon
DecidedJanuary 4, 2012
DocketCase No. 03:11-cv-00366-HU
StatusPublished

This text of 840 F. Supp. 2d 1251 (Biotronik, Inc. v. Medtronic USA, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Oregon primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Biotronik, Inc. v. Medtronic USA, Inc., 840 F. Supp. 2d 1251, 2012 WL 14031, 2012 U.S. Dist. LEXIS 890 (D. Or. 2012).

Opinion

[1253]*1253OPINION AND ORDER

SIMON, District Judge.

INTRODUCTION

In this lawsuit, Plaintiff seeks only declaratory relief. Plaintiff originally filed this action in state court in Clackamas County, Oregon, and Defendants removed the case to this court under 28 U.S.C. § 1441, asserting diversity jurisdiction under 28 U.S.C. § 1332(a). Plaintiff moves to remand the lawsuit to state court (Doc. 17) under 28 U.S.C. § 1447(c), arguing that the amount in controversy does not satisfy the $75,000 threshold required for diversity jurisdiction. Defendants move to dismiss the case for improper venue or, in the alternative, to transfer venue. (Doc. 8). On September 29, 2011, United States Magistrate Judge Dennis Hubei issued findings and recommendations (“F & R”) on these two motions and referred them to this court (Doc. 43).

In his F & R, Judge Hubei recommends that Plaintiffs motion to remand be granted. He also recommends that, if this court were to find that the amount in controversy requirement has been satisfied, Defendants’ motion to dismiss for improper venue and alternative motion to transfer should be denied. Defendants objected to both recommendations. The court heard oral argument on November 9, 2011.

Under the Federal Magistrates Act, the court may “accept, reject or modify, in whole or in part, the findings or recommendations made by the magistrate.” Federal Magistrates Act, 28 U.S.C. § 636(b)(1). If a party files objections to a magistrate’s findings and recommendations, “the court shall make a de novo determination of those portions of the report or specified proposed findings or recommendations to which objection is made.” Id.; Fed.R.Civ.P. 72(b)(3). De novo review means that the reviewing court “considers the matter anew, as if no decision had been rendered.” Dawson v. Marshall, 561 F.3d 930, 933 (9th Cir.2009) (citation omitted).

The court has reviewed the matter de novo and accepts in part and rejects in part Judge Hubei’s F & R. The court rejects Judge Hubei’s first recommendation that Plaintiffs motion to remand be granted. For the reasons stated below, the court finds that the amount in controversy requirement has been satisfied. Thus, Plaintiffs motion to remand is DENIED. The court accepts Judge Hubei’s second recommendation for the reasons stated by Judge Hubei. Thus, Defendant’s motion to dismiss and alternative motion to transfer is DENIED.

BACKGROUND

Plaintiff, Biotronik, Inc. (“Biotronik”), is an Oregon corporation. Defendants, Medtronic USA, Inc. and Medtronic, Inc. (collectively, “Medtronic”), are Minnesota corporations. Biotronik and Medtronic are competitors engaged in the sale and marketing of cardiac rhythm management (“CRM”) devices, which use electrical pulses to treat improperly beating hearts and other cardiac diseases. As alleged in the complaint and discussed by Judge Hubei:

The market in which the parties compete is extremely competitive, and the devices they sell are technologically complex. As such, their sales personnel not only must be skilled salespeople, they also must have a great deal of technical and clinical knowledge, and as a result, they receive considerable training. To protect their investment in their employees, as well as the proprietary information to which their employees are privy, the parties “require their CRM sales representatives and managers to sign employment agreements that include post-termination noncompetition, confidentiality, and non-solicitation obli[1254]*1254gations (the “PosNTermination Obligations”).

F & R, at 2:20-3:3 (citations omitted).

Rory Carmichael (“Carmichael”), who is not a party in this lawsuit, worked for Medtronic from 1997 through January 2009. In 1997, Medtronic hired Carmichael as a district sales manager. In 2005, Medtronic promoted Carmichael to regional vice president of Medtronic’s Florida region. Both at the time of his initial employment and upon his promotion to vice president, Carmichael signed an employee agreement with Medtronic (the “Employee Agreement”) that includes Post-Termination Obligations.1 Carmichael’s last day of work for Medtronic was January 6, 2009.2 In connection with his separation from Medtronic, Carmichael and Medtronic signed a Separation Agreement and Release (the “Separation Agreement”) on January 29, 2009.3 In addition to other provisions, Carmichael’s Separation Agreement expressly preserves certain duties and obligations set forth in his Employee Agreement, including the Post-Termination Obligations.

In addition, Carmichael’s Separation Agreement provides in Article 2.1 for certain “transition period compensation” (the “Transition Period Compensation”) and in Article 2.2 for certain additional consideration (the “Additional Consideration”), both to be paid by Medtronic to Carmichael, subject to certain conditions. The parties agree that the precise amounts of the Transition Period Compensation and the Additional Consideration should be kept confidential for business reasons and that it is factually correct and not confidential to say that the Transition Period Compensation and the Additional Consideration are each well in excess of the $75,000 threshold amount in controversy required for diversity jurisdiction under 28 U.S.C. § 1332(a).

Article 2.3 of Carmichael’s Separation Agreement with Medtronic describes certain forms of “Prohibited Conduct,” many of which are similar to the Post-Termination Obligations. Among other things, Article 2.3(4) provides that, until the close of business on January 6, 2011, Carmichael may not, without the express written permission of Medtronic, “solicit, directly or indirectly, any person employed by Medtronic [in certain areas and during a certain time period] to work for any other employer.” A similar restriction appears in Carmichael’s Employee Agreement at Section 4.2, under the heading “Section 4: Posh-Employment Restrictions.”

Article 2.4(c) of Carmichael’s Separation Agreement provides, among other things, that if a court determines that Carmichael has violated Article 2.3 of the Separation Agreement, Carmichael must promptly repay to Medtronic the Additional Consideration payments made pursuant to Article 2.2 (the “Repayment Amount”). Medtronic refers to this Repayment Amount as “liquidated damages.” In addition, Article 2.4(b) of the Separation Agreement provides that Medtronic may “terminate all payments pursuant to Articles 2.1 [the Transition Period Compensation] and 2.2 [the Additional Consideration] if Carmichael materially breaches any other provision of this Agreement or the Employee Agreement.”

[1255]

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
840 F. Supp. 2d 1251, 2012 WL 14031, 2012 U.S. Dist. LEXIS 890, Counsel Stack Legal Research, https://law.counselstack.com/opinion/biotronik-inc-v-medtronic-usa-inc-ord-2012.